The DOI matches its Crossref record.
Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism
Abstract
Azathioprine therapy can cause acute myelosuppression. Toxicity is in part caused by the incorporation of azathioprine-derived 6-thioguanine nucleotides (6-TGN) into deoxyribonucleic acid (DNA). The enzyme thiopurine methyltransferase (TPMT) plays an important role in azathioprine catabolism. TPMT activity is controlled by a common genetic polymorphism, and one in 300 subjects has very low enzyme activity. Azathioprine was withdrawn in five study patients because of acute myelosuppression. The duration of azathioprine treatment was 21 to 70 days (median, 28), and the daily oral dose was 1.0 to 2.5 mg/kg. Sixteen control patients who had been taking oral azathioprine (1.1 to 2.0 mg/kg daily for more than 6 months) with no history of myelosuppression were studied. All subjects had normal liver and kidney function. When compared with the control group, the five patients with myelosuppression had very low TPMT activities and abnormally high 6-TGN concentrations. Inherited low TPMT activity appears to be a major risk factor for acute azathioprine-induced myelosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Self-citationDubinsky, M. C., Lamothe, S., Yang, H. Y., Targan, S. R., Sinnett, D., Théorêt, Y., & Seidman, E. G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70140-5 · Cited by 996
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Self-citationThe clinical pharmacology of 6-mercaptopurine
Lennard, L. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220605 · Cited by 647
Self-citationClinical application of pharmacogenetics
Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01986-4 · Cited by 646
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D., & SINGER, G. G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11suppl_1s1 · Cited by 634
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 604
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C.-H., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.320 · Cited by 574
Diagnosis and treatment of autoimmune hepatitis
Czaja, A. J., & Freese, D. K. (2002) · Hepatology · doi:10.1053/jhep.2002.34944 · Cited by 563
Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.19 · Cited by 549
Self-citationBone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
Connell, W. R., Kamm, M. A., Ritchie, J. K., & Lennard-Jones, J. E. (1993) · Gut · doi:10.1136/gut.34.8.1081 · Cited by 510
Karran, P., & Attard, N. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2292 · Cited by 477
Taylor, A. L., Watson, C. J. E., & Bradley, J. A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.012 · Cited by 445
Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D., & Roberts, W. M. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83063-x · Cited by 392
Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*
Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J. O., Iven, H., Schmiegelow, K., Branum, E., O'Brien, J., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90152-1 · Cited by 390
Self-citationAzathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis
Johnson, P. J., McFarlane, I. G., & Williams, R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331502 · Cited by 382
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Marinaki, A. M., Ansari, A., Duley, J. A., Arenas, M., Sumi, S., Lewis, C. M., Shobowale-Bakre, E.-M., Escuredo, E., Fairbanks, L. D., & Sanderson, J. D. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00006 · Cited by 323
Pharmacogenomics: bench to bedside
Weinshilboum, R., & Wang, L. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1497 · Cited by 320
Self-citationSZUMLANSKI, C., OTTERNESS, D., HER, C., LEE, D., BRANDRIFF, B., KELSELL, D., SPURR, N., LENNARD, L., WIEBEN, E., & WEINSHILBOUM, R. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.17 · Cited by 305
Self-citationThe thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics
McLeod, H. L., & Siva, C. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.1.89 · Cited by 296
Meggitt, S. J., Gray, J. C., & Reynolds, N. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68340-2 · Cited by 285
Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6444 · Cited by 259
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Gisbert, J. P., & Gomolln, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01848.x · Cited by 253
Pharmacogenomics: Catechol-O-methyltransferase to thiopurine S-methyltransferase
Weinshilboum, R. M. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9095-z · Cited by 66
“As a result, patients homozygous for TPMT alleles associated with low levels of enzyme activity have elevated 6-TGNs when they are treated with standard doses of thiopurines and are at greatly increased risk for life-threatening drug-induced myelosuppression ( Lennard et al., 1987, 1989, 1990; Evans et al., 1991; Sch…”
BackgroundSelf-citation
Metadata
- Authors
- Lennard, L., Van Loon, J. A., & Weinshilboum, R. M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1989-08
- Volume
- 46
- Issue
- 2
- Pages
- 149-154
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2029841402
- Cited by
- 593
- References
- 0
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.